The University of Southampton
University of Southampton Institutional Repository

Clinical outcomes following neoadjuvant cisplatin-based chemotherapy for bladder cancer in elderly compared with younger patients

Clinical outcomes following neoadjuvant cisplatin-based chemotherapy for bladder cancer in elderly compared with younger patients
Clinical outcomes following neoadjuvant cisplatin-based chemotherapy for bladder cancer in elderly compared with younger patients
Bladder cancer is a disease of the elderly. Older patients might potentially be undertreated due to assumptions about benefit versus risk. Our objective was to determine outcomes in older patients receiving neoadjuvant chemotherapy for muscle-invasive bladder cancer (MIBC). We hypothesised that appropriately selected elderly patients (?70 years) with MIBC could have similar clinical outcomes, and be safely treated, with standard neoadjuvant chemotherapy prior to definitive cystectomy or radiotherapy. We utilised a single institution case series analysis of patients with T2-4a N0 M0 transitional cell carcinoma of the bladder treated with cisplatin-based neoadjuvant chemotherapy between 2005 and 2011. Eighty-three patients were eligible. Median age was 68 (range 48–80), 33 patients (40%) were ?70 years. Overall survival at 3 years was 65.8% (?70) and 63.2% (<70) (P = 0.653), relapse-free survival at 3 years was 61.6% and 54.8% respectively (P = 0.471). The rates going forward to definitive local therapy (87.9% ? 70 and 84.0% < 70) and the pathological complete response rate (31.3% ? 70 and 40% < 70) were similar. Disease relapse rate was also similar (63.6% ? 70 vs. 60% < 70, P = 0.906). Elderly patients with good functional status and limited comorbidities diagnosed with MIBC receiving standard neoadjuvant chemotherapy followed by cystectomy or radiotherapy can have similar clinical outcomes as their younger counterparts. Prospective studies evaluating the optimum curative management in this elderly population are warranted.
elderly, bladder cancer, chemotherapy, cisplatin, outcome
0961-5423
1-8
Chau, C.
bc5b21b2-4974-4992-806f-61e90fc5ea63
Wheater, M.
85400f31-13b9-4327-b52e-c4519be149d9
Geldart, T.
829fdbee-84dd-4825-b5eb-0e6e859ba9ff
Crabb, S.J.
bcd1b566-7677-4f81-8429-3ab0e85f8373
Chau, C.
bc5b21b2-4974-4992-806f-61e90fc5ea63
Wheater, M.
85400f31-13b9-4327-b52e-c4519be149d9
Geldart, T.
829fdbee-84dd-4825-b5eb-0e6e859ba9ff
Crabb, S.J.
bcd1b566-7677-4f81-8429-3ab0e85f8373

Chau, C., Wheater, M., Geldart, T. and Crabb, S.J. (2015) Clinical outcomes following neoadjuvant cisplatin-based chemotherapy for bladder cancer in elderly compared with younger patients. European Journal of Cancer Care, 1-8. (doi:10.1111/ecc.12282). (PMID:25620269)

Record type: Article

Abstract

Bladder cancer is a disease of the elderly. Older patients might potentially be undertreated due to assumptions about benefit versus risk. Our objective was to determine outcomes in older patients receiving neoadjuvant chemotherapy for muscle-invasive bladder cancer (MIBC). We hypothesised that appropriately selected elderly patients (?70 years) with MIBC could have similar clinical outcomes, and be safely treated, with standard neoadjuvant chemotherapy prior to definitive cystectomy or radiotherapy. We utilised a single institution case series analysis of patients with T2-4a N0 M0 transitional cell carcinoma of the bladder treated with cisplatin-based neoadjuvant chemotherapy between 2005 and 2011. Eighty-three patients were eligible. Median age was 68 (range 48–80), 33 patients (40%) were ?70 years. Overall survival at 3 years was 65.8% (?70) and 63.2% (<70) (P = 0.653), relapse-free survival at 3 years was 61.6% and 54.8% respectively (P = 0.471). The rates going forward to definitive local therapy (87.9% ? 70 and 84.0% < 70) and the pathological complete response rate (31.3% ? 70 and 40% < 70) were similar. Disease relapse rate was also similar (63.6% ? 70 vs. 60% < 70, P = 0.906). Elderly patients with good functional status and limited comorbidities diagnosed with MIBC receiving standard neoadjuvant chemotherapy followed by cystectomy or radiotherapy can have similar clinical outcomes as their younger counterparts. Prospective studies evaluating the optimum curative management in this elderly population are warranted.

Full text not available from this repository.

More information

Accepted/In Press date: 3 December 2014
Published date: 2015
Keywords: elderly, bladder cancer, chemotherapy, cisplatin, outcome
Organisations: Cancer Sciences

Identifiers

Local EPrints ID: 373717
URI: https://eprints.soton.ac.uk/id/eprint/373717
ISSN: 0961-5423
PURE UUID: 592271f3-3bf1-4a87-b8c7-9673c5e3e36c

Catalogue record

Date deposited: 27 Jan 2015 11:49
Last modified: 17 Jul 2017 21:32

Export record

Altmetrics

Contributors

Author: C. Chau
Author: M. Wheater
Author: T. Geldart
Author: S.J. Crabb

University divisions

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of https://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×